Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
43°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
30.10
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
30.10
Bid (Size)
12.04 (2)
Ask (Size)
47.85 (1)
Prev. Close
30.10
Today's Range
30.10 - 30.10
52wk Range
21.99 - 38.09
Shares Outstanding
53,145,884
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
April 29, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+8.55%
+8.55%
1 Month
-10.20%
-10.20%
3 Month
+6.17%
+6.17%
6 Month
+26.21%
+26.21%
1 Year
-18.54%
-18.54%
More News
Read More
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
April 08, 2024
Via
Benzinga
Exposures
Product Safety
Recap: Supernus Pharmaceuticals Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
Supernus Pharmaceuticals: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 08, 2024
Via
Benzinga
Supernus Provides Regulatory Update for SPN-830
April 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotechnology And Healthcare, A Bit Of A Lull
March 25, 2024
Via
Talk Markets
Supernus to Participate in Two Upcoming Investor Conferences
March 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 13, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 05, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
December 14, 2023
Via
InvestorPlace
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
December 12, 2023
Via
Benzinga
Exposures
Product Safety
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 8, 2023
November 08, 2023
Via
Benzinga
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
November 02, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
October 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
October 16, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
October 02, 2023
Via
Benzinga
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
September 27, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.